X

Trial Profile

A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Thalidomide (Primary)
Indications Carcinoma; Sarcoma; Uterine cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

18 Jul 2012 Planned End Date changed from 1 May 2008 to 1 Jan 2013 as reported by ClinicalTrials.gov.
14 Oct 2009 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University).
30 Jun 2009 New source identified and integrated (New Jersey Cancer Trial Connect).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com